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Risk Factors for Major Adverse Cardiovascular Events in 
Phase III and Long- Term Extension Studies of Tofacitinib in 
Patients With Rheumatoid Arthritis
Christina Charles-Schoeman,1 Ryan DeMasi,2 Hernan Valdez,3 Koshika Soma,4 Lie-Ju Hwang,3 Mary G. Boy,4 
Pinaki Biswas,3 and Iain B. McInnes5
Objective. Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was under-
taken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib.
Methods. Data were pooled from patients with moderately to severely active RA receiving ≥1 tofacitinib dose 
in 6 phase III and 2 long- term extension studies over 7 years. MACE (myocardial infarction, stroke, cardiovascular 
death) were independently adjudicated. Cox regression models were used to evaluate associations between baseline 
variables and time to first MACE. Following 24 weeks of tofacitinib, changes in variables and time to future MACE 
were evaluated after adjusment for age, baseline values, and time- varying tofacitinib dose. Hazard ratios and 95% 
confidence intervals were calculated.
Results. Fifty- two MACE occurred in 4,076 patients over 12,873 patient- years of exposure (incidence rate 0.4 
patients with events per 100 patient- years). In univariable analyses of baseline variables, traditional cardiovascular 
risk factors and glucocorticoid and statin use were associated with MACE risk; disease activity and inflammation 
measures were not. In subsequent multivariable analyses, baseline age, hypertension, and the total cholesterol to 
high- density lipoprotein (HDL) cholesterol ratio remained significantly associated with risk of MACE. After 24 weeks 
of treatment, an increase in HDL cholesterol and a decrease in the total to HDL cholesterol were associated with 
decreased MACE risk; changes in total cholesterol, low- density lipoprotein (LDL) cholesterol, and disease activity 
measures were not. Increased erythrocyte sedimentation rates trended with increased future MACE risk.
Conclusion. In this post hoc analysis, after 24 weeks of tofacitinib treatment, increased HDL cholesterol, but not 
increased LDL cholesterol or total cholesterol, appeared to be associated with lower future MACE risk. Further data 
are needed to test the cardiovascular safety of tofacitinib.
INTRODUCTION
Cardiovascular disease (CVD) is one of the most common 
comorbidities in patients with rheumatoid arthritis (RA), with a 
prevalence of 9.3% for any CV event (1). Compared with the gen-
eral population, patients with RA have an increased risk of CVD (2) 
and higher rates of CVD- induced mortality (3). As a consequence, 
CVD is the leading cause of death in patients with RA, accounting 
for almost 31% of mortality (4).
Traditional CV risk factors, such as hypertension, smok-
ing, and type 2 diabetes mellitus, contribute to the increased 
risk of CVD among patients with RA as they do in the general 
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 population (5,6); however, after adjustment for traditional risk 
factors, a  proportion of the increased CV risk in patients with RA 
remains unexplained (7). A key driver of increased CV risk in RA 
appears to be the high systemic inflammatory burden. There is 
an  apparent inverse relationship between inflammation and lipid 
levels in patients with RA, such that increased inflammation is 
associated with reduced lipid levels and also with changes in the 
composition of lipid profiles (8).
The relationship between lipid levels and CV risk in patients 
with RA is complex. Within the general population, an increased 
risk of CVD is associated with high serum total cholesterol, high 
serum low- density lipoprotein (LDL) cholesterol, and low serum 
high- density lipoprotein (HDL) cholesterol levels (9,10). Individuals 
with an elevated total cholesterol to HDL cholesterol ratio have 
an increased risk of developing CVD, and the total cholesterol to 
HDL cholesterol ratio has been shown to be a reliable predictor of 
CVD risk (11). In contrast, in patients with active RA, increased risk 
of CVD has been associated with relatively lower levels of serum 
total cholesterol and LDL cholesterol, as well as HDL cholesterol. 
These lower lipid levels may be driven by inflammation associated 
with RA (12,13). In RA, changes are also seen in the composition 
and function of HDL particles; previous studies have shown that 
active disease is associated with impaired antioxidative function 
of HDL, decreased HDL- mediated cholesterol efflux, and alter-
ations in the levels and function of several HDL- associated pro-
teins (14–16).
Overall CV risk in patients with RA is affected by disease 
activity and likely by the resultant systemic inflammation. In a pre-
vious study by Maradit- Kremers et al, high clinical disease activ-
ity, as measured by 3 erythrocyte sedimentation rates (ESRs) of 
≥60 mm/hour, correlated with a 2- fold increased risk of death from 
CVD in an inception cohort of 603 patients (17). In the same cohort 
of 172 patients who developed congestive heart failure (CHF), the 
proportion of patients with an ESR of ≥40 mm/hour was high-
est during the 6- month period immediately preceding CHF onset 
(18). Other studies have demonstrated associations of markers of 
inflammation with subclinical atherosclerosis (19,20). Finally, in a 
post hoc analysis of data from patients with RA treated with the 
interleukin- 6 (IL- 6) receptor inhibitor tocilizumab, increases in dis-
ease activity measures, such as the Disease Activity Score in 28 
joints (DAS28) score (21) and joint counts, were associated with 
risk of future major adverse CV events (MACE), while changes in 
lipid levels were not (22).
It is unclear whether there are differential effects of RA ther-
apeutics on CV outcomes. In previous studies, treatment with 
disease- modifying antirheumatic drugs (DMARDs), such as 
methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi), 
has been shown to reduce the probability of CV events (23,24). 
In the ENTRACTE study, which evaluated CV events in patients 
receiving tocilizumab versus etanercept, 83 MACE occurred 
over 4,900 patient- years in the tocilizumab arm, compared with 
78 MACE over 4,891 patient- years in the etanercept arm (haz-
ard ratio 1.05 [95% confidence interval 0.77–1.43]) (25). Taken 
together, these findings highlight the importance of investigating 
CV risk factors in patients with RA, as well as the effects of thera-
pies for RA on the risk of MACE.
Tofacitinib is an oral JAK inhibitor for the treatment of RA. 
Formal comparison of the effect of tofacitinib on the risk of MACE 
is currently being investigated in a phase IIIb/IV prospective com-
parative study with TNFi (NCT02092467) (26). MACE is also 
being evaluated in patients receiving tofacitinib versus biologic 
DMARDs and conventional synthetic DMARDs in a real- world 
setting using data from the Corrona registry and the following 
European registries: British Society for Rheumatology Biologics 
Register (BSRBR), Anti- Rheumatic Therapy in Sweden (ARTIS), 
Rheumatoide Arthritis: Beobachtung der Biologika- Therapie 
(RABBIT), and Base de Datos de Productos Biológicos de la 
Sociedad Española de Reumatología (BIOBADASER). However, 
during phase II studies, tofacitinib treatment was associated with 
increased LDL cholesterol and HDL cholesterol levels in patients 
with RA (27–31). Consequently, phase III and long- term exten-
sion (LTE) studies included adjudication of potential CV events and 
deaths. In a pooled analysis of phase III data, tofacitinib treatment 
was associated ~10–20% of the increases in total cholesterol, 
HDL cholesterol, and LDL cholesterol levels from baseline to week 
4, which were maintained to week 24. Changes in lipid levels sta-
bilized after 12 weeks of tofacitinib treatment, and this was asso-
ciated with a low incidence of CV events (32). The objective of the 
present post hoc analysis was to determine whether changes in 
lipids levels following administration of tofacitinib were associated 
with an increased risk of MACE in patients with RA enrolled in 
phase III and LTE studies.
PATIENTS AND METHODS
Design of phase III and LTE studies. Patients with RA 
participated in 1 of 6 randomized, double- blind phase III studies 
and/or 2 open- label LTE studies (for study names and details, see 
Supplementary Table 1, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40911/ 
abstract). Inclusion and exclusion criteria have been previously 
described (33–41). Briefly, patients were age ≥18 years, with active 
RA that fulfilled the American College of Rheumatology 1987 crite-
ria (42), and had active disease at screening and baseline.
All studies were conducted in compliance with the Declara-
tion of Helsinki and the Good Clinical Practice Guidelines estab-
lished by the International Conference for Harmonisation. The 
study protocols were approved by the institutional review board 
or independent ethics committee at each center. All patients 
 provided written informed consent.
Two of the phase III studies evaluated tofacitinib 5 and 
10 mg twice daily as monotherapy: ORAL Solo (NCT00814307), 
a 6- month study of tofacitinib versus placebo in patients with 
an inadequate response to DMARDs (34) and ORAL Start 
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(NCT01039688), a 24- month study of tofacitinib versus MTX in 
MTX- naive patients (36).
The remaining 4 phase III studies evaluated tofacitinib 5 and 
10 mg twice daily in combination with conventional synthetic 
DMARDs versus placebo, as follows: ORAL Scan (NCT00847613), 
a 24- month study of tofacitinib in patients with an inadequate 
response to MTX who were receiving background MTX (37); 
ORAL Stan dard (NCT00853385), a 12- month study in patients 
with an inadequate response to MTX who were receiving back-
ground MTX (38); ORAL Sync (NCT00856544), a 12- month study 
of tofacitinib in combination with conventional synthetic DMARDs 
in patients with an inadequate response to DMARDs (35); and 
ORAL Step (NCT00960440), a 6- month study in patients with 
an inadequate response to TNFi who were receiving background 
MTX (33).
The 2 open- label LTE studies (ORAL Sequel; NCT00413699 
[database not locked at the time of analysis] and NCT00661661) 
enrolled patients who had completed phase I, phase II, or phase III 
index studies of tofacitinib. Regardless of treatment assignment 
in the qualifying index study, patients began treatment in the LTE 
studies with tofacitinib 5 or 10 mg twice daily (with the exception 
of Chinese and Japanese patients who received 5 mg twice daily 
per protocol), and were subsequently allowed to switch doses 
(39–41). In all studies, adverse events were recorded verbatim by 
the investigator and coded according to the Medical Dictionary for 
Regulatory Activities (MedDRA), version 13.0.
Figure 1. Univariable analyses of associations between baseline variables and the occurrence of major adverse cardiovascular events (MACE) 
during tofacitinib treatment. For all continuous variables, unit = 1 unless specified otherwise; in unit = x, “x” is the change in the continuous 
variable corresponding to which the change in hazards is observed. * = smoking status as recorded at baseline; † = including any of the 
Medical Dictionary for Regulatory Activities–coded terms: angina pectoris, arrhythmia, atrial flutter, atrial fibrillation, first- degree atrioventricular 
block, left bundle branch block, cardiac failure, cardiac failure congestive, cardiac valve disease, cardiomegaly, cardiomyopathy, coronary 
artery disease, hypertensive cardiomyopathy, left ventricular hypertrophy, mitral valve incompetence, mitral valve prolapse, valve prolapse, 
myocardial infarction, palpitations, sinus bradycardia, sinus tachycardia, tachycardia, tachycardia paroxysmal, tricuspid valve incompetence, 
and ventricular extrasystole; ‡ = based on prior medical history; § = based on both use of diabetes medication and medical history. n = number 
of patients with future MACE for each baseline variable; N = number of patients included in the analysis for each baseline variable; HR = hazard 
ratio; 95% CI = 95% confidence interval; BMI = body mass index; DAS28- 4 (ESR) = 4- variable Disease Activity Score in 28 joints using the 
erythrocyte sedimentation rate; CRP = C- reactive protein; MTX = methotrexate; RA = rheumatoid arthritis; TC = total cholesterol; HDL- c = high- 
density lipoprotein cholesterol; LDL- c = low- density lipoprotein cholesterol. 
RISK OF MACE IN PATIENTS WITH RA FOLLOWING TOFACITINIB TREATMENT |      1453
Post hoc analyses. The current post hoc analyses included 
all patients with RA who received at least 1 dose of tofacitinib 
5 or 10 mg twice daily in the phase III and LTE studies and had 
exposure after week 24 (patients who had MACE before week 
24, or who had withdrawn or completed the study before week 
24 were excluded). As patients in the LTE studies were allowed 
to switch doses, patients were assigned into 5 or 10 mg twice 
daily treatment groups based on their average total daily dose 
(TDD; calculated by adding all doses received by each patient, 
and dividing by the number of days a dose was received). Patients 
were assigned to the 5 mg twice daily group if the TDD was <15 
mg/day, and to the 10 mg twice daily group if it was ≥15 mg/day 
(43).
MACE, defined as any myocardial infarction (MI), cerebro-
vascular event (stroke), or CV death (defined as death caused 
by coronary, cerebrovascular, or cardiac events), were identified 
during the assessment of safety end points during the phase III 
and LTE studies. Patients were evaluated until withdrawal from the 
Figure 2. Multivariable analyses of associations between baseline variables and the occurrence of MACE during tofacitinib treatment. For all 
continuous variables, unit = 1 unless specified; in unit = x, “x” is the change in the continuous variable corresponding to which the change in 
hazards is observed. Only variables with significant associations with occurrence of MACE are shown; this analysis also included baseline body 
mass index and time- varying tofacitinib dosage (both not significant). See Figure 1 for definitions. 
Figure 3. Multivariable analyses of associations between changes in variables after 24 weeks of tofacitinib treatment and the risk of future 
MACE. For each variable listed, a Cox regression model was fit, with change in the variable at week 24, the variable at baseline, age at baseline, 
and time- varying dosage as predictors. In this model, only patients with exposure after week 24 were considered (i.e., patients who had MACE 
before week 24 or who had withdrawn or completed the study by week 24 were excluded). Patients with missing data for the week- 24 variable 
were excluded from the analysis of that variable (no imputation method). The HR corresponds to increased risk of MACE per 1- unit increase in 
the parameter. n = number of patients with future MACE for each predictor; N = number of patients included in the analysis for each predictor; 
PGA = patient global assessment; VAS = visual analog scale (see Figure 1 for other definitions). 
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study, completion of the study, or the initial occurrence of MACE, 
 whichever occurred first. In the event of multiple occurrences of 
MACE, only the first was counted.
Only adjudicated events were included in the analysis. Adju-
dication of MACE started in October 2009 with the chartering of 
the CV Safety Event Adjudication Committee (CVSEAC). Events 
reported prior to October 2009 were not adjudicated and are 
therefore not included in this analysis. The CVSEAC was retired in 
November 2013 and a new committee, the CV Event Adjudication 
Committee, was established. Both committees comprised inde-
pendent, external experts in the fields of CV and/or neurovascular 
disease.
Statistical analysis. Baseline demographic and disease 
characteristics were summarized descriptively for patients with 
and without MACE. Cox regression models were used to evaluate 
the associations between baseline (pre- tofacitinib) covariate val-
ues and time to first MACE, in univariable analyses (each covari-
ate assessed singly) (Figure 1) and multivariable analysies (several 
covariates included together in 1 model) (Figures 2 and 3). The 
covariates included in the multivariable analysis were age, history 
of hypertension, total cholesterol to HDL cholesterol ratio, baseline 
body mass index (BMI), and time- varying tofacitinib dosage (Fig-
ure 2). A second multivariable analysis was carried out using the 
same variables, but included history of diabetes mellitus instead of 
baseline BMI. A final model was selected via backward elimination 
with stay criteria at 15%. Associations were expressed as hazard 
ratios and 95% confidence intervals.
Cox regression models were also used to separately evalu-
ate the associations between changes in the predictors of MACE 
from baseline to week 24 and the time to future development of 
MACE (defined as the first occurrence of MACE after 24 weeks), 
after adjustment for age, baseline values of covariates, and time- 
varying tofacitinib dosage in a multivariable analysis (Figure 3). For 
each risk factor, the analysis included age, baseline value, and 
change from baseline to week 24; other risk factors were not 
included in the same model.
The time- varying tofacitinib dosage was a time- dependent 
covariate, and was determined by the time of first onset of MACE. 
If the first onset of MACE occurred during the index study, the 
randomized dosage in the index study was used. If the first onset 
of MACE occurred during the LTE study, then the average of the 
tofacitinib dosage (5 or 10 mg twice daily) was used.
For all analyses of covariates, unadjusted P values less 
than or equal to 0.05 were considered significant. No multiplicity 
adjustment was carried out, as this was a post hoc analysis for 
exploratory purposes.
RESULTS
Tofacitinib exposure and patient disposition. The 
analysis population included 4,076 patients, representing a total of 
12,932 patient- years of tofacitinib exposure. In total, 52 patients 
had adjudicated MACE, resulting in a total of 12,873 patient- years 
of exposure for the event and an incidence rate of 0.4 patients 
with events per 100 patient- years of exposure (95% confidence 
interval 0.3–0.5), as of March 2015. There were 12 cases of CV 
death (cardiac death, n = 8; cerebrovascular death, n = 2; non-
cardiac/other vascular death, n = 2 [acute cardiac failure, n = 1; 
cerebral hemorrhage, n = 1]), 19 cases of nonfatal MI, and 23 
Table  1. Baseline demographic characteristics of patients with 
and patients without MACE*
Characteristic
No MACE 
(n = 4,024)
Adjudicated MACE 
(n = 52)
Age, mean ± SD years 52.7 ± 11.9 60.2 ± 10.4
Female, no. (%) 3,334 (82.9) 43 (82.7)
BMI, mean ± SD kg/m2 27.0 ± 6.4 29.2 ± 8.2
History of CHD, no. (%) 21 (0.5) 0 (0.0)
History of cardiac 
disorders, no. (%)†
199 (4.9) 4 (7.7)
History of diabetes 
mellitus, no. (%)‡
307 (7.6) 8 (15.4)
Abnormal BP, no. (%)§ 334 (8.3) 4 (7.7)
History of hyperten-
sion, no. (%)
1,358 (33.7) 30 (57.7)
Smoking status, no. (%)
Never 676 (16.8) 14 (26.9)
Current 678 (16.8) 11 (21.2)
Ex- smoker¶ 2,667 (66.3) 27 (51.9)
Concomitant 
medications
Glucocorticoids,  
no. (%)
1,909 (47.4) 18 (34.6)
Statins, no. (%) 420 (10.4) 12 (23.1)
NSAIDs, no. (%) 2,817 (70.0) 34 (65.4)
MTX, no. (%) 2,443 (60.7) 36 (69.2)
MTX dose,  
mean ± SD mg
15.0 ± 4.7 14.9 ± 4.0
* MACE = major adverse cardiovascular event; BMI = body mass 
index; CHD = coronary heart disease; NSAIDs = nonsteroidal anti-
inflammatory drugs; MTX = methotrexate. 
† Including any of the Medical Dictionary for Regulatory Activi-
ties–coded terms: angina pectoris, arrhythmia, atrial flutter, atrial 
fibrillation, first- degree atrioventricular block, left bundle branch 
block, cardiac failure, cardiac failure congestive, cardiac valve dis-
ease, cardiomegaly, cardiomyopathy, coronary artery disease, 
hypertensive cardiomyopathy, left ventricular hypertrophy, mitral 
valve incompetence, mitral valve prolapse, valve prolapse, myocar-
dial infarction, palpitations, sinus bradycardia, sinus tachycardia, 
tachycardia, tachycardia paroxysmal, tricuspid valve incompe-
tence, and ventricular extrasystole. 
‡ Based on both use of diabetes medication and medical history. 
§ Defined as systolic blood pressure (BP) of >150 mm Hg or diastolic 
BP of >90 mm Hg. 
¶ Defined as those who had smoked previously but were not 
smokers at baseline. 
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cases of nonfatal stroke. Two patients had multiple categories of 
MACE (1 patient had a nonfatal stroke and a nonfatal MI, and 1 
patient had a nonfatal stroke, followed by cerebrovascular death).
The baseline demographic characteristics of patients with 
and without adjudicated MACE are shown in Table  1. Overall, 
compared with patients without MACE, patients with MACE were 
older (mean age 52.7 years versus 60.2 years), had a higher mean 
BMI (27.0 versus 29.2 kg/m2), were more likely to have a history 
of diabetes mellitus (7.6% versus 15.4%) or hypertension (33.7% 
versus 57.7%), and were more likely to be receiving concomitant 
statins (10.4% versus 23.1%).
The baseline disease characteristics of patients with and 
without adjudicated MACE are shown in Table 2. Compared 
with patients without MACE, patients with MACE had a longer 
mean disease duration (7.7 years versus 10.1 years), slightly 
higher mean total cholesterol levels (198.3 versus 208.2 mg/
dl), LDL cholesterol levels (113.9 versus 123.3 mg/dl), total 
cholesterol to HDL cholesterol ratio (3.5 versus 4.0), and tri-
glyceride levels (125.3 versus 152.1 mg/dl), and slightly lower 
HDL  cholesterol levels (59.4 versus 55.3 mg/dl) at  baseline.
Baseline predictors of MACE. In univariable analy-
ses, risk of MACE was significantly associated with older age, 
higher BMI, statin use, or longer duration of RA. Other baseline 
predictors that were associated with a significantly increased 
risk of MACE were elevated levels of triglycerides, higher total 
cholesterol to HDL cholesterol ratio, elevated apolipoprotein 
B (Apo B) levels, higher Apo B to Apo A- 1 ratio, abnormal 
blood pressure, history of hypertension, and history of diabe-
tes  mellitus (Figure 1).
In contrast, glucocorticoid use was associated with a sig-
nificantly lower risk of MACE (mean ± SD glucocorticoid dosage 
at baseline 3.5 ± 4.4 and 3.3 ± 6.4 mg/day for patients receiving 
tofacitinib 5 mg and 10 mg twice daily, respectively, and 3.9 ± 
4.1 and 3.4 ± 3.9 mg/day for patients receiving placebo who 
advanced to tofacitinib 5 mg and 10  mg twice daily, respec-
tively). Baseline disease activity and inflammation measures, 
including the 4- variable DAS28 using the ESR (21), ESR and 
C- reactive protein level, and swollen and tender joint counts, 
were not significantly associated with MACE risk (Figure 1).
In separate multivariable analyses, patient age, history of 
hypertension, and the total cholesterol to HDL cholesterol ratio 
continued to be significantly associated with an increased risk of 
MACE (Figure 2). The findings of the multivariable analyses were 
consistent across all selection methods used (backward, forward, 
and stepwise selection). Time- varying tofacitinib dosage and 
baseline BMI were not found to be associated with risk of MACE in 
this analysis. Furthermore, in a second multivari able analysis that 
included history of diabetes mellitus in place of baseline BMI, his-
tory of diabetes mellitus was also not associated with MACE risk.
Changes in predictors of MACE between baseline and 
week 24. Previously, tofacitinib treatment was found to be associ-
ated with increases in total cholesterol, HDL cholesterol, and LDL 
cholesterol levels (32), and baseline and week 24 values for the other 
covariates included in the analysis are shown in Supplementary 
Table 2 (available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40911/ abstract). The effects 
of 24 weeks of treatment with tofacitinib (and tofacitinib- associated 
increases in lipid levels) on the risk of future MACE were assessed 
by multivariable analyses (Figure 3). After adjustment for age, time- 
varying tofaciti nib dosage, and the baseline value for each variable, 
increases in HDL cholesterol levels and decreases in the total cho-
lesterol to HDL cholesterol ratio after 24 weeks of tofacitinib were 
associated with a reduced risk of MACE. In contrast, increases in 
total cholesterol levels and LDL cholesterol levels were not asso-
ciated with increased risk of future MACE. A trend was observed 
between increases in ESR after 24 weeks of tofacitinib treatment 
and an increase in the future risk of MACE, although this did not 
reach statistical significance. Changes in disease activity measures, 
such as the 4- variable DAS28 using the ESR, and swollen and ten-
der joint counts, were not associated with increased risk of future 
MACE.
DISCUSSION
In this post hoc analysis of data from phase III and LTE 
studies of tofacitinib, we assessed the associations between 
Table  2. Baseline disease characteristics in patients with and 
patients without MACE*
Characteristic
No MACE 
(n = 4,024)
Adjudicated 
MACE 
(n = 52)
Duration of RA, years 7.7 ± 7.9 10.1 ± 8.8
4- variable DAS28- ESR 6.3 ± 1.1 6.3 ± 1.3
Tender joint count 14.1 ± 7.3 14.3 ± 7.5
Swollen joint count 10.4 ± 5.6 10.3 ± 5.9
Total cholesterol, mg/dl 198.3 ± 42.1 208.2 ± 48.9
HDL cholesterol, mg/dl 59.4 ± 16.9 55.3 ± 16.0
LDL cholesterol, mg/dl 113.9 ± 34.2 123.3 ± 43.2
Total cholesterol to HDL 
cholesterol ratio 
3.5 ± 1.1 4.0 ± 1.5
Triglycerides, mg/dl 125.3 ± 72.6 152.1 ± 86.9
Apolipoprotein A- 1,  
mg/dl
153.6 ± 31.2 149.4 ± 27.8
Apolipoprotein B, mg/dl 94.4 ± 24.7 105.8 ± 29.4
CRP, mg/dl 17.1 ± 22.7 15.7 ± 16.9
ESR, mm/hour 50.4 ± 26.9 47.9 ± 23.8
* Values are the mean ± SD. MACE = major adverse cardiovascu-
lar event; RA = rheumatoid arthritis; DAS28- ESR = Disease Activity 
Score in 28 joints using the erythrocyte sedimentation rate; HDL 
= high- density lipoprotein; LDL = low- density lipoprotein; CRP = 
C- reactive protein; ESR = erythrocyte sedimentation rate. 
CHARLES-­SCHOEMAN­ET­AL­1456       |
baseline  variables and time to first MACE as well as the changes 
in  variables after 24 weeks of tofacitinib treatment and time to 
future MACE.
In univariable analyses of baseline variables, an increased 
risk of MACE was associated with the presence of traditional 
risk factors at baseline (such as older age, higher BMI, abnormal 
blood pressure, and history of either hypertension or diabetes 
mellitus), elevated baseline triglyceride and Apo B levels, and 
higher baseline Apo B to Apo A- 1 ratio and total cholesterol to 
HDL cholesterol ratio. In subsequent multivariable analysis of 
baseline measures, age, history of hypertension, and the total 
cholesterol to HDL cholesterol ratio continued to be associated 
with an increased risk of MACE.
The analyses of baseline variables in this study are consis-
tent with large population studies of CV outcomes, reinforcing the 
finding that traditional CV risk factors are important to CV risk in 
patients with RA (17). They also reinforce the findings from pre-
vious studies that have demonstrated the association between 
MACE risk and both traditional risk factors and Apo B to Apo A- 1 
and total cholesterol to HDL cholesterol ratios in patients with RA 
(22,44). In addition, the European League Against Rheumatism 
guidelines on management of CV risk in patients with RA suggest 
that the total cholesterol to HDL cholesterol ratio is a particularly 
important indicator of CV risk (45).
Risk of MACE was not associated with measures of disease 
activity or inflammation at baseline in this analysis. A previous 
study by Rao et al, which investigated risk factors for MACE in 
patients with RA during treatment with tocilizumab, also showed 
no association between risk of MACE and baseline measures of 
inflammation, but did demonstrate an association between the 
risk of MACE and baseline disease activity measures (22).
The present analyses also suggest an association between 
baseline statin use and risk of future MACE. However, this obser-
vation was potentially due to confounding by indication, as 
patients with RA who had the highest CV risk as judged by their 
physicians were more likely to be taking a statin at baseline.
In a previous pooled analysis, which assessed lipid concen-
trations in the same patient population as the current analysis, 
increased total, HDL, and LDL cholesterol levels were observed 
in patients receiving tofacitinib (32). We evaluated the effects of 
24 weeks of tofacitinib treatment on risk of MACE in multivariable 
analyses and found that increases in HDL cholesterol levels and 
decreases in the total cholesterol to HDL cholesterol ratio were 
associated with reduced risk of future MACE in multivariable anal-
yses, while increases in total cholesterol and LDL cholesterol lev-
els were not. Rao et al also found no association of CV risk with 
total cholesterol and LDL cholesterol levels following 24 weeks 
of tocilizumab treatment. However, in contrast with our findings, 
increases in HDL cholesterol were not associated with risk of 
MACE following tocilizumab treatment in their study (22).
Higher HDL cholesterol levels have previously been associ-
ated with a decreased risk of MI in patients with active RA (46,47). 
However, cholesteryl ester transfer protein inhibitors, which also 
increase HDL cholesterol levels, have failed to confer consistent 
reductions in CV events in clinical trials in the general population 
(48). Therefore, the association between modulation of HDL cho-
lesterol level and risk of MACE remains unresolved. Consequently, 
additional consideration should be given to mechanisms inde-
pendent of increases in HDL cholesterol levels, such as improved 
HDL particle function, which has been linked to CV outcomes in 
the general population (49). Previous studies have suggested that 
tofacitinib may improve the function of HDL particles via increases 
in the activity of the HDL- associated enzyme paraoxonase 1 
(50). In addition, during the MEASURE study, “normalization” of 
HDL particle composition was observed in a detailed analysis of 
lipoprotein subfractions following tocilizumab treatment (51), and 
a small- scale study of rituximab in patients with RA showed a 
reduction in proatherogenic HDL particle composition (52). Fur-
thermore, cholesterol ester fractional catabolism, which is higher 
in patients with active RA than in the general population, was 
reduced following tofacitinib treatment, and this reduction was 
also associated with improvements in HDL functional markers and 
correlated significantly with increased HDL cholesterol levels (53). 
Therefore, the effects of tofacitinib treatment on CV risk are likely 
to be multifactorial and may include changes in lipoproteins that 
are independent of cholesterol levels, such as changes in HDL 
composition and/or cholesterol ester fractional catabolism (53).
The present study also showed a trend toward an asso-
ciation of elevated ESR following tofacitinib treatment with an 
increased risk of future MACE, and this is consistent with find-
ings in a population- based study of CV death, which suggested 
that patients with RA who have sustained elevation of ESR may 
have a higher risk of CV death (17). One possible explanation 
for this higher risk is that increased ESR may be a surrogate of 
failure to respond. In contrast to these findings, Rao et al (22) 
did not demonstrate changes in ESR to be associated with 
future risk of MACE following tocilizumab treatment; addition-
ally, increases in DAS28 scores and swollen and tender joint 
counts were associated with higher CV risk in their study but 
not in ours. The disparities between our results and the findings 
of Rao et al may be due to differences in the pharmacokinet-
ics/pharmacodynamics of tocilizumab and tofacitinib as well as 
the overall small number of CV events in both trial programs. 
In addition, while IL- 6–induced JAK/STAT signal transduction 
as a driver of CV events is well established in atherosclerosis 
(54), inflammatory processes are myriad and complex, with both 
multiple upstream activators and diverse downstream targets in 
different cell types. Therefore, tocilizumab inhibition of IL- 6 and 
tofacitinib inhibition of JAK/STAT may have different effects in 
the downstream inflammation process and may, therefore, have 
contrasting effects on lipid levels.
This study had a number of limitations. The data were 
obtained from a post hoc analysis of data pooled from 6 phase 
III and 2 LTE studies that were not designed to evaluate future 
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MACE risk. Consequently, the number of patients and exposure 
times in this study were low, as were the number of adjudicated 
MACE. The adjudication process changed in November 2013 
from consensus- based to blinded independent review, and 
there were also changes in the individuals conducting adjudi-
cation as well as changes from committee- created definitions of 
events to Food and Drug Administration−approved definitions 
(55). These procedural changes may have introduced variables 
into the adjudication outputs. Also, several covariates, including 
disease activity and measures of inflammation, as well as time- 
varying confounders such as hypertension, statin use, and glu-
cocorticoids, were only assessed at baseline in the multivariable 
analyses and this may not be sufficient to predict CV events with 
this sample size. Furthermore, we recognize that while the back-
ward elimination method is the simplest to implement and most 
intuitive to explain, it may not always identify the best subset of 
variables or covariates for retention in the model. In this analysis, 
consistent results were also observed with forward and step-
wise elimination methods. In addition, this study did not evaluate 
HDL and LDL particle size, or HDL particle function. As a con-
sequence of these limitations, direct interpretation of the results 
may be confounded.
In conclusion, in pooled analyses of tofacitinib- treated 
patients, traditional CV risk factors at baseline appeared to 
be associated with an increased risk of future MACE, while 
no apparent association was observed between future risk of 
MACE and baseline disease activity or measures of inflamma-
tion. Following adjustment for age, baseline values, and time- 
varying tofaciti nib dosage, increases in HDL cholesterol and 
decreases in the total cholesterol to HDL cholesterol ratio were 
associated with reduced future MACE risk after 24 weeks of 
tofacitinib treatment, while increases in LDL cholesterol and 
total cholesterol were not associated with future MACE risk. 
Increases in ESR after 24 weeks of tofacitinib therapy may be 
associated with increased future MACE risk and, conversely, a 
decrease in inflammation as measured by ESR with tofacitinib 
may convey some CV protection. More data are needed to con-
firm these findings, which could be beneficial in future profiling of 
tofacitinib- treated patients with RA who may be at greatest risk 
of MACE. The CV event safety of tofacitinib versus adalimumab 
or etanercept in patients with RA is currently being investigated 
in a phase IIIb/IV randomized open- label study (A3921133; 
NCT02092467) (26).
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